Search research articles
Contact Us
Filters
Showing results (1-10 of 168) with videos related to
Page
of 17
Sort By:
The Lancet. Oncology
|
November 26, 2015
DPD deficiency in patients treated with fluorouracil
Joseph Ciccolini
Current Topics in Medicinal Chemistry
|
September 18, 2012
Editorial: targeted therapy, targeted dosing and targeted delivery in oncology: where do we stand?
Joseph Ciccolini
Trends in Pharmacological Sciences
|
November 16, 2007
Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
Cédric Mercier, Joseph Ciccolini
British Journal of Cancer
|
October 29, 2023
Immune check points in cancer treatment: current challenges and perspectives
Joseph Ciccolini, Gerard Milano
JAMA Oncology
|
June 10, 2016
Women at a Disadvantage in Fluorouracil Treatment
Joseph Ciccolini, Gérard Milano
Clinical Colorectal Cancer
|
January 24, 2007
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy
Cédric Mercier, Joseph Ciccolini
Expert Opinion on Drug Metabolism & Toxicology
|
December 16, 2014
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs
Cindy Serdjebi, Gérard Milano, Joseph Ciccolini
JCO Precision Oncology
|
October 2, 2025
Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction
Govind Kallee, Gerard Milano, Joseph Ciccolini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2012
A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter
Joseph Ciccolini, Alexandre Evrard, Bruno Lacarelle
British Journal of Cancer
|
December 8, 2020
COVID-19 vaccine race: watch your step for cancer patients
Raphaelle Fanciullino, Joseph Ciccolini, Gerard Milano
Page
of 17
Search research articles
Search
Showing results (1-10 of 168) with videos related to
Sort By:
Page
of 17
The Lancet. Oncology
|
November 26, 2015
DPD deficiency in patients treated with fluorouracil
Joseph Ciccolini
Current Topics in Medicinal Chemistry
|
September 18, 2012
Editorial: targeted therapy, targeted dosing and targeted delivery in oncology: where do we stand?
Joseph Ciccolini
Trends in Pharmacological Sciences
|
November 16, 2007
Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
Cédric Mercier, Joseph Ciccolini
British Journal of Cancer
|
October 29, 2023
Immune check points in cancer treatment: current challenges and perspectives
Joseph Ciccolini, Gerard Milano
JAMA Oncology
|
June 10, 2016
Women at a Disadvantage in Fluorouracil Treatment
Joseph Ciccolini, Gérard Milano
Clinical Colorectal Cancer
|
January 24, 2007
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy
Cédric Mercier, Joseph Ciccolini
Expert Opinion on Drug Metabolism & Toxicology
|
December 16, 2014
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs
Cindy Serdjebi, Gérard Milano, Joseph Ciccolini
JCO Precision Oncology
|
October 2, 2025
Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction
Govind Kallee, Gerard Milano, Joseph Ciccolini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2012
A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter
Joseph Ciccolini, Alexandre Evrard, Bruno Lacarelle
British Journal of Cancer
|
December 8, 2020
COVID-19 vaccine race: watch your step for cancer patients
Raphaelle Fanciullino, Joseph Ciccolini, Gerard Milano
Page
of 17